Becton, Dickinson and Company (BDX)
NYSE · Healthcare · Medical Instruments & Supplies
$180.67+2.19%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $49.2B
- P/E (trailing)
- 42.0
- Forward P/E
- 13.6
- Dividend yield
- 2.3%
- 52-week range
- $127.59 – $193.07
- 52-week change
- +16.81%
- EPS (trailing)
- $4.30
- Analyst rating
- 2.1 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Sep 2025
- Revenue
- $21.8B (+8.24%)
- Net income
- $1.7B
- Operating margin
- 11.8%
- Diluted EPS
- $5.82
From the company’s annual report on SEC EDGAR.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems.
Headquarters: Franklin Lakes, United States · 72,000 employees · bd.com